Series A Financing led by EcoR1 Capital, Jeito Capital and Syncona with continued assist of strategic seed consumers Vida Ventures, TPG and Two River
Neogene’s proprietary experience platform identifies specific T cell receptor (TCR) genes from routine tumor samples using state-of-the-art synthetic biology devices
Co-founded by renowned T cell engineering educated Ton Schumacher, Ph.D. and Carsten Linnemann, Ph.D. with funding from cell treatment enterprise veteran Arie Belldegrun, M.D. FACS
NEW YORK & AMSTERDAM–(BUSINESS WIRE)–September 14, 2020–
Neogene Therapeutics, Inc., a pre-clinical stage biotechnology agency pioneering a model new class of completely personalised neo-antigen T cell therapies to cope with most cancers, proper this second launched that it has raised $110 million in a Series A financing. The financing was co-led by EcoR1 Capital, Jeito Capital and Syncona, with participation from Polaris Partners and Pontifax. Seed consumers Vida Ventures, TPG and Two River moreover participated inside the spherical.
Neogene, a Two River agency, was primarily based in 2018 by a workers of world-class cell treatment specialists to advance the occasion of neo-antigen T cell therapies. Carsten Linnemann, Ph.D., Chief Executive Officer of Neogene, and Ton Schumacher, Ph.D., Principal Investigator on the Netherlands Cancer Institute, Oncode Institute and 2020 recipient of the Dutch Research Council’s Stevin Award co-founded the Company with specific particular person investments by cell treatment enterprise veterans Arie Belldegrun, M.D. FACS, founding father of Kite Pharma, Inc. and Co-Founder and Executive Chairman of Allogene Therapeutics, Inc. and David Chang, M.D., Ph.D., Co-Founder, President and Chief Executive Officer of Allogene. Dr. Linnemann and Dr. Schumacher beforehand co-founded T-Cell Factory B.V., a company acquired by Kite Pharma in 2015.
Dr. Schumacher, an internationally predominant immunologist inside the areas of neo-antigen biology and T cell engineering, developed the seminal concepts of Neogene’s proprietary experience. Neogene’s platform permits for the isolation of neo-antigen specific TCR genes from tumor biopsies which is perhaps routinely obtained from most cancers victims all through treatment. The tumor-infiltrating lymphocytes (TIL) obtained by these tumor biopsies usually categorical TCRs specific for mutated proteins current in most cancers cells (neo-antigens). The Company’s proprietary experience makes use of state-of-the-art DNA sequencing, DNA synthesis and genetic screening devices to set up such neo-antigen specific T cell receptor genes inside tumor biopsies with extreme sensitivity, specificity and at scale. The isolated TCR genes are subsequently engineered into T cells of most cancers victims to provide large numbers of potent T cells for treatment.
“Neogene is committed to forging a path for new fully personalized engineered T cell therapies in solid cancer that are redirected towards neo-antigens found on cancer cells,” said Dr. Linnemann. “While engineered T cell therapies have transformed the treatment paradigm for patients with hematologic malignancies, the industry has struggled to translate this success to the enormous unmet need in patients with advanced solid tumors. We believe that through a fully individualized approach using patient-specific TCRs to target neo-antigens, engineered T cell therapy can become broadly accessible to these patients. We are excited that our vision is shared by an outstanding syndicate of marquee investors, who have a deep understanding of and commitment towards the development of novel cell therapies in oncology.”
“Neo-antigens represent ideal targets for cancer therapy, as they inevitably arise from DNA mutations that enable tumor development in the first place. Further supporting this concept is clear, correlative evidence linking T cell reactivity against neo-antigens with tumor regression in several patients,” said Dr. Schumacher. “The Neogene platform makes it possible to exploit the neo-antigen reactive TCRs that are present in TIL without a requirement for viable tumor material. In addition, its syn-bio based approach offers major advantages with respect to standardization and scalability and will be critical to achieve our goal of bringing personalized engineered T cell therapies to patients.”
In this Series A financing, Neogene expands its distinguished investor base with predominant health-care consumers from every the U.S. and Europe. For the seed-investors Vida Ventures, TPG and Two River, Neogene marks the second predominant collaboration inside the cell treatment home after the launch of Allogene Therapeutics in 2018. Neogene’s seed-financing in 2019 enabled the Company to attain proof-of-concept for its neo-antigen experience platform and constructed on the respective expertise of Vida Ventures, Two River and TPG inside the gene and cell treatment home.
“We believe that Neogene’s technology and therapeutic approach has the potential to become a game changer for the treatment of cancer,” said Oleg Nodelman, Founder and Managing Director of EcoR1 Capital. “We are impressed by the bold vision of the management team and are thrilled to support Neogene as it advances its mission of developing novel therapies for cancer patients in need.”
“Neogene’s approach perfectly aligns with Jeito’s mission. Jeito was launched recently to support new and established entrepreneurs aspiring to help patients in need by pioneering novel, ground-breaking medicines underlined by highest quality innovation,” said Rafaèle Tordjman, Founder and Chief Executive Officer at Jeito Capital. “We are delighted to welcome Neogene as the first investment into our new portfolio.”
“We are excited to partner with the outstanding Neogene team,” said Martin Murphy, Chief Executive Officer of Syncona. “Neogene’s technology offers a radically innovative approach to utilize the therapeutic potential of TIL cells by employing state-of-the-art TCR engineering and synthetic biology technologies.” Facilitated by the Series A, Neogene intends to extra develop its experience with rising locations of labor in Amsterdam and the U.S. with the target to provoke Phase I scientific analysis in 2022.
About Neogene Therapeutics
Neogene Therapeutics, Inc. is a pre-clinical stage biotechnology agency pioneering enchancment of next-generation, completely personalised engineered T cells therapies for a broad spectrum of cancers. The Company’s engineered T cells aim mutated proteins current in most cancers cells due to cancer-associated DNA mutations, or neo-antigens, that render tumor cells weak to detection by T cells. Neogene’s proprietary experience platform targets to set up TCR genes with specificity for neo-antigens from tumor biopsies. Neogene’s novel methodology intends to ship a tailored set of TCR genes for each specific particular person affected particular person, which is able to seemingly be engineered into patient-derived T cells directing them in path of neo-antigens in tumor cells, with the target of providing a very personalised engineered T cell treatment for many cancers.
Carsten Linnemann, Ph.D.
Chief Executive Officer
Neogene Media Contact: